"The team at HCD Economics are ‘creative, responsive, knowledgeable, expert, agile, conscientious and reliable!’"
Burden of illness pharmaceutical industry partner
"I’ve worked with HCD Economics on a range of projects with excellent results including literature reviews, real world evidence generation and analyses, validation of outcomes measures, and designing outcomes studies. The team are very knowledgeable, very responsive to communications and always engaged in understanding the project requirements and the wider strategic requirements. I would not hesitate in recommending HCD Economics."
"At the British Liver Trust, we have been alarmed at the sharp increase in the number of people being diagnosed with NASH (non-alcoholic steatohepatitis) in the UK. They are often relatively young people in the prime of their lives and the diagnosis often comes as a complete shock. There has been scant research into the impact of NASH on patients’ quality of life, and on the direct and indirect costs of NASH to individuals and society. That is why the British Liver Trust welcomes the GAIN (Global Assessment of the Impact of NASH) study and is pleased to be involved in the research with HCD Economics."
Judi Rhys, CEO at BLT (British Liver Trust)